Skip to Main content Skip to Navigation
Journal articles

Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone

Robin Arcani 1 Geoffroy Venton 2, 1 Julien Colle 2, 1 Pierre Suchon 3 Vadim Ivanov 1 Cédric Mercier 1 Laure Farnault 1 Pauline Roche 1 Marina Lafage 4 Corinne Brunet 1 Wakil Azouza 1 Bertrand Pourroy 1 Raphaelle Fanciullino 1 Régis Costello 2, 1
1 LA CONCEPTION - Hôpital de la Conception [CHU - APHM]
2 TAGC - Theories and Approaches of Genomic Complexity
3 Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM]
4 Laboratoire de Génie Génétique [Hôpital de la Timone - APHM]
Abstract : Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.
Keywords : bortezomib immunomodulatory therapy lenalidomide multiple myeloma
Document type :
Journal articles
Complete list of metadatas

Cited literature [29 references]  Display  Hide  Download
https://hal-amu.archives-ouvertes.fr/hal-02267221
Contributor : Lionel Spinelli <>
Submitted on : Friday, October 18, 2019 - 9:52:29 AM
Last modification on : Saturday, November 21, 2020 - 3:09:27 AM
Long-term archiving on: : Sunday, January 19, 2020 - 1:05:14 PM

Files

Vignette du document
Revised Manuscript VRD EJH Fin...
Files produced by the author(s)

Identifiers

Collections

UNIV-AMU

Citation

Robin Arcani, Geoffroy Venton, Julien Colle, Pierre Suchon, Vadim Ivanov, et al.. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. European Journal of Haematology, Wiley, 2019, ⟨10.1111/ejh.13297⟩. ⟨hal-02267221⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

210

Files downloads

483